{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ge C"],"funding":["China Postdoctoral Science Foundation","National Natural Science Foundation of China","Nanjing Science and Technology Development Foundation","Jiangsu postdoctoral grant program"],"pagination":["14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9887786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Background
As a prodrug of 5-fluorouracil (5-FU), orally administrated capecitabine (CAP) undergoes preliminary conversion into active metabolites in the liver and then releases 5-FU in the gut to exert the anti-tumor activity. Since metabolic changes of CAP play a key role in its activation, a single kind of intestinal or hepatic cell can never be used in vitro to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) nature. Hence, we aimed to establish a novel in vitro system to effectively assess the PK and PD of these kinds of prodrugs.Methods
Co-culture cellular models were established by simultaneously using colorectal cancer (CRC) and hepatocarcinoma cell lines in one system. Cell Counting Kit-8 (CCK-8) and flow cytometric analysis were used to evaluate cell v"],"journal":["Cancer cell international"],"pubmed_title":["In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer."],"pmcid":["PMC9887786"],"funding_grant_id":["2018Z092","81803624","202205029","81803622","2018M640498"],"pubmed_authors":["Ge C","Zou J","Zhang J","Zhu Y","Xu C","Feng D","Yuan M","Zhang S","Jie Q","Aa J","Tan Z","Zhang Y","Huang X"],"additional_accession":[]},"is_claimable":false,"name":"In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer.","description":"Background
As a prodrug of 5-fluorouracil (5-FU), orally administrated capecitabine (CAP) undergoes preliminary conversion into active metabolites in the liver and then releases 5-FU in the gut to exert the anti-tumor activity. Since metabolic changes of CAP play a key role in its activation, a single kind of intestinal or hepatic cell can never be used in vitro to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) nature. Hence, we aimed to establish a novel in vitro system to effectively assess the PK and PD of these kinds of prodrugs.Methods
Co-culture cellular models were established by simultaneously using colorectal cancer (CRC) and hepatocarcinoma cell lines in one system. Cell Counting Kit-8 (CCK-8) and flow cytometric analysis were used to evaluate cell v","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T09:19:20.864Z","creation":"2025-04-04T09:19:20.864Z"},"accession":"S-EPMC9887786","cross_references":{"pubmed":["36717845"],"doi":["10.1186/s12935-023-02853-6"]}}